Why Choose EverydayMeds for Your Complete Dose Journey?
Complete Wegovy and Mounjaro Doses Range: Your Entire Treatment Journey
Understanding Wegovy and Mounjaro doses becomes crucial when planning long-term weight management. Both prescription-only medicines require identical dose escalation: starting at 0.25mg weekly, progressing through 0.5mg and 1mg, reaching 1.7mg, then maintaining at 2.4mg from week 17 onwards. EverydayMeds stocks every dose strength continuously, meaning you'll never face treatment interruptions due to supply shortages. This comprehensive availability eliminates the stress of switching pharmacies mid-treatment, which can disrupt your progress and relationship with healthcare providers.
The difference lies in their mechanisms: Wegovy contains semaglutide (a GLP-1 receptor agonist), whilst Mounjaro contains tirzepatide (a dual GIP and GLP-1 receptor agonist). Both require clinical assessment and prescriber approval, but having access to complete Wegovy and Mounjaro doses means your healthcare provider can switch between treatments if needed. Our clinical team at EverydayMeds (GPhC #9012878) ensures seamless transitions, maintaining your momentum towards weight management goals.
Wegovy and Mounjaro Doses: Transparent Pricing Across All Strengths
Wegovy and Mounjaro doses follow different pricing structures reflecting their development costs and manufacturing complexity. Wegovy pricing starts at £79.99 for 0.25mg (weeks 1-4), progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for 2.4mg maintenance doses. New customers apply code FIRST40 at checkout, whilst returning customers use DOSE25 to reach these final prices. Our Intro Duo bundle (0.25mg and 0.5mg) costs £169.99, covering your first 8 weeks conveniently.
Mounjaro follows similar dose escalation but with different pricing due to its dual-receptor mechanism. Both treatments require identical monitoring and dose progression, but understanding the cost implications helps budget for long-term treatment. Our Step-Up Trio bundles provide 12-week supplies: Intro Trio (0.25mg, 0.5mg, 1mg) for £299.99, or Progress Trio (0.5mg, 1mg, 1.7mg) for £369.99. These bundles ensure treatment continuity whilst providing predictable monthly costs for budgeting purposes.
Clinical Evidence Supporting Wegovy and Mounjaro Doses Effectiveness
The STEP clinical trial programme demonstrates Wegovy and Mounjaro doses' effectiveness when combined with reduced-calorie diet and increased physical activity. In STEP 1, patients taking Wegovy alongside lifestyle interventions achieved approximately 15% average weight loss at 68 weeks, compared to 2.4% with placebo (Wilding et al., NEJM, 2021). The dose escalation protocol proved essential for tolerability, with most participants successfully reaching 2.4mg maintenance doses.
Mounjaro's SURMOUNT trials showed the importance of proper dose escalation in achieving optimal outcomes. Both treatments require the same progression through Wegovy and Mounjaro doses: four weeks at each strength before advancing. This gradual increase allows your body to adapt whilst minimising gastrointestinal side effects. Clinical evidence consistently shows better long-term adherence when patients complete full dose escalation rather than attempting to rush progression.
Understanding How Wegovy Works Across Different Doses
Wegovy's active ingredient, semaglutide, functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormones that regulate appetite and blood sugar. As you progress through Wegovy and Mounjaro doses, the increasing medication levels more effectively activate these receptors in your brain's appetite control centres. The 0.25mg starting dose begins this process gently, whilst the 2.4mg maintenance dose provides sustained appetite suppression and enhanced satiety signals. This mechanism explains why you feel fuller after smaller meals and experience reduced food cravings throughout treatment. The dose escalation isn't just about tolerability—each increase strengthens the medication's ability to regulate your appetite naturally, supporting long-term weight management alongside dietary changes and exercise.
Streamlined Ordering Process for All Wegovy and Mounjaro Doses
Accessing Wegovy and Mounjaro doses through EverydayMeds begins with our 3-minute online clinical assessment, designed to evaluate your suitability for either treatment. Our prescribers review applications within 3 working days (or 24 hours with express service), considering your BMI, medical history, and weight management goals. Once approved, we dispatch your prescription-only medicine via next-day delivery using temperature-controlled packaging to maintain medication integrity. Our system automatically tracks your dose progression, sending timely reminders when you're ready to advance to the next strength. This proactive approach ensures you never run out of medication or delay progression through the established Wegovy and Mounjaro doses schedule, maintaining treatment momentum essential for optimal outcomes.
Storage and Practical Considerations for Wegovy and Mounjaro Doses
Understanding storage requirements becomes crucial when managing Wegovy and Mounjaro doses throughout your treatment journey. Both medications require refrigeration at 2-8°C before first use, but Wegovy offers superior travel flexibility with 6 weeks of room temperature stability versus Mounjaro's 21 days. This advantage proves valuable during holidays or business travel when refrigeration access might be limited. Both treatments use similar FlexTouch pen technology, making transitions between Wegovy and Mounjaro doses straightforward if your prescriber recommends switching. The pre-loaded pens eliminate dosing errors and provide consistent delivery across all strength levels. Each pen contains four weekly doses, and the escalation schedule ensures you'll use one pen monthly until reaching maintenance dosing, where 2.4mg pens also provide four weeks of treatment.
Comprehensive Dose Management: Your Complete Treatment Timeline
Planning your journey through Wegovy and Mounjaro doses requires understanding the complete 17-week escalation timeline leading to lifelong maintenance therapy. EverydayMeds' unique advantage lies in stocking every dose continuously, eliminating common treatment disruptions caused by supply shortages affecting single-strength pharmacies. Our inventory management ensures immediate availability whether you're starting at 0.25mg or maintaining at 2.4mg, providing the consistency essential for successful weight management.
This comprehensive approach extends beyond simple stock availability—our clinical team monitors your progression through Wegovy and Mounjaro doses, adjusting timelines if tolerability issues arise. Some patients benefit from extended periods at intermediate doses, whilst others progress smoothly through the standard schedule. Having immediate access to all dose strengths allows personalised treatment plans without compromising your momentum or forcing premature progression due to supply constraints affecting other pharmacies.
Expert Support Throughout Your Wegovy and Mounjaro Doses Journey
Starting treatment with either medication means committing to long-term weight management, and having expert support throughout your Wegovy and Mounjaro doses progression proves invaluable. Our clinical team at EverydayMeds (GPhC #9012878) provides ongoing guidance as you advance through each dose level, addressing concerns and optimising your treatment plan alongside dietary modifications and exercise programmes. We understand that both Wegovy and Mounjaro require lifestyle changes to achieve optimal results, and our support extends beyond simple medication supply to comprehensive care coordination. Ready to begin your journey? Use code FIRST40 for new customers or DOSE25 for returning patients at https://everydaymeds.co.uk/collections/wegovy. Our complete dose range ensures continuity from your first injection through lifelong maintenance, providing the stability essential for sustained weight management success alongside a reduced-calorie diet and increased physical activity.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
